Indivior Reports Third-Quarter Revenue of $356 Million
Story updates
11:07:25 AM UTC
SquawkNews
Indivior reported third-quarter 2026 revenue of $356 million, up 13% year over year, and record net income of $137 million. Adjusted EBITDA rose 76% to $211 million, with a 59% margin. The company said its merger with Supernus is expected to close November 2.Financial HighlightsBusiness HighlightsO…
11:34:08 AM UTC
SquawkNews
Indivior Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, featuring total net revenue of $356 million, a 13% increase year-over-year. The company achieved record quarterly net revenue of $267 million for its SUBLOCADE product, representing 22% growth compared to the same period last year. Additionally, the company reported record quarterly net income of $137 million and record adjusted EBITDA of $211 million, with an adjusted EBITDA margin of 59%. Management noted that the company remains on track to achieve its previously communicated 2026 financial guidance and is preparing for the imminent closing of its merger with Supernus on November 2, 2026.